Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 141Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Ramucirumab 33Trastuzumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × titanium silicide × Gastrointestinal × Clear all
NCT01285557 2024-09-19

DIGEST

Taiho Oncology, Inc.

Phase 3 Terminated
361 enrolled 18 charts
Gastrointestinal

Stomach Neoplasms

NCT03382600 2024-06-11

KEYNOTE-659

Merck Sharp & Dohme LLC

Phase 2 Completed
100 enrolled 21 charts
Gastrointestinal

Stomach Neoplasms

NCT00429858 2020-09-18

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

University of California, San Francisco

Phase 2 Terminated
21 enrolled 8 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡